Shares of Tempest Therapeutics (TPST) ended higher on Wednesday amid a broader market rebound on the U.S. pausing tariffs and ...

Since the Orphan Drug Act went into effect in 1983, more than 600 drugs have been approved for rare diseases, according to ...

EMA orphan drug designation is awarded to drugs intended to treat rare diseases that are life-threatening or chronically ...

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free ...

AscellaHealth has announced its role as a Silver Sponsor of the World Orphan Drug Congress USA (WODC), which will convene ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that ...

The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, ...

About IgG4-RD IgG4-RD affects approximatively eight out of 100,000 adult patients in the US each year and is a rare, progressive, relapsing, chronic fibro-inflammatory condition which can manifest in ...

French biotech Pep-Therapy SAS is in the midst of raising a €20 million (US$21.62 million) round and, at the same time, prospecting for potential partners after winning FDA orphan drug designation for ...

AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, proudly announces its role as a Silver Sponsor at the World Orphan Drug Congress USA ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...